Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Thrombomodulin].

Y Ohmori1, Y Takahashi

  • 1Research Center, Mochida Pharmaceutical Co. Ltd., 722, Jimba-Aza-Uenohara, Gotemba 412-8524, Japan.

Nihon Yakurigaku Zasshi. Folia Pharmacologica Japonica
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Benefit of electron beam therapy in combination with medium-dose systemic corticosteroid as a palliative treatment for elderly patients with blastic plasmacytoid dendritic cell neoplasm: case report and review of the literature.

Clinical and experimental dermatology·2018
Same author

Ingestion of paddy rice increases intestinal mucin secretion and goblet cell number and prevents dextran sodium sulfate-induced intestinal barrier defect in chickens.

Poultry science·2018
Same author

Comparison of dynamic contrast-enhanced 3T MR and 64-row multidetector CT angiography for the localization of spinal dural arteriovenous fistulas.

AJNR. American journal of neuroradiology·2013
Same author

A 6-fr guiding catheter (slim guide(®)) for use with multiple microdevices. An experimental study.

Interventional neuroradiology : journal of peritherapeutic neuroradiology, surgical procedures and related neurosciences·2013
Same author

Evaluation of antireflection coatings for optical waveguides.

Applied optics·2010
Same author

Negative coupling of ?-aminobutyric acid (GABA)(B) receptor with phosphatidylinositol turnover in the brain.

Neurochemistry international·2010
Same journal

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Prediction of severe oral mucositis in cancer treatment: the role of the oral-gut axis in precision supportive care].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Iron dysregulation and ferroptosis in heart failure: the dual faces of deficiency and overload].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological characteristics and clinical outcomes of Rimegepant (Nurtec<sup>®</sup> ODT), an oral CGRP receptor antagonist for the acute treatment and prevention of migraine].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Pharmacological properties and clinical trial results of datopotamab deruxtecan (Dato-DXd, Datroway<sup>®</sup>)].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
Same journal

[Oxytocin regulates social familiarity-dependent mate choice in medaka].

Nihon yakurigaku zasshi. Folia pharmacologica Japonica·2026
See all related articles

Soluble thrombomodulin (MR-33) from human urine shows potent anticoagulant effects by enhancing protein C activation. It effectively treats disseminated intravascular coagulation (DIC) in animal models with a low risk of bleeding.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Hematology

Context:

  • Thrombomodulin (TM) regulates coagulation as a thrombin receptor on endothelial cells.
  • Soluble TM exists in human plasma and urine.
  • Disseminated intravascular coagulation (DIC) is a life-threatening condition requiring effective treatment.

Purpose:

  • To investigate the anticoagulant and anti-inflammatory effects of soluble TM purified from human urine (MR-33).
  • To evaluate the efficacy and safety of MR-33 in preclinical models of thrombosis and inflammation.

Summary:

  • MR-33 purified from human urine demonstrated significant anticoagulant activity in vitro by inhibiting thrombin and accelerating protein C activation.
  • In vivo studies using rat DIC models showed MR-33 improved hematological parameters with a favorable benefit-risk ratio regarding bleeding.

Related Experiment Videos

  • MR-33 also exhibited anti-inflammatory effects by preventing endotoxin-induced increases in inflammatory markers and vascular permeability in mice.

    • Impact:

    • MR-33 shows potential as a novel antithrombotic agent for treating DIC with a reduced risk of hemorrhage.
    • Its efficacy in heparin-resistant models and anti-inflammatory properties suggest broad therapeutic applications.
    • Clinical trials are underway in Japan for MR-33 in DIC treatment.